Hepcludex (bulevirtide) / Hepatera, Gilead - LARVOL DELTA

Final results of MYR301: a randomised phase 3 study evaluating the efficacy and safety of up to 144 weeks of bulevirtide monotherapy for chronic hepatitis delta and 96 weeks of posttreatment follow-up (EASL 2025) - No abstract available

Clinical • Late-breaking abstract • Monotherapy • P3 data • Hepatology • Inflammation

Health-related quality of life in patients with chronic hepatitis D receiving bulevirtide and pegylated interferon: interim results from the SEE-D clinical trial (EASL 2025) - No abstract available

Clinical • HEOR • Hepatology • Inflammation

Gilead: Achievable toDay: Expert insights on HDV patient management (EASL 2025) - "Sponsored by Gilead. To increase healthcare providers' knowledge in the use of bulevirtide by providing an expert perspective on key selected topics and scenarios, including approaches to patient screening, treatment eligibility in paediatric and adult populations, treatment initiation, on-treatment considerations and treatment optimisation."

Clinical • Hepatology • Pediatrics

Virological response and safety of combination treatment with bulevirtide and pegylated interferon in chronic hepatitis D patients with advanced fibrosis/cirrhosis: 48 weeks interim results from SEE-D trial (EASL 2025) - No abstract available

Clinical • Metastases • Fibrosis • Hepatology • Immunology • Inflammation

Treatment response to bulevirtide leads to improvement of portal hypertension in patients with chronic hepatitis D virus infection: results from the prospective IMPHROVE-D study (EASL 2025) - No abstract available

Clinical • Cardiovascular • Hepatology • Infectious Disease • Inflammation • Portal Hypertension

Long risk of decompensation and HCC in patients with HDV-related compensated cirrhosis treated with Bulevirtide monotherapy for up to 144 weeks: the retrospective multicenter european study (Save-D) (EASL 2025) - No abstract available

Monotherapy • Retrospective data • Fibrosis • Hepatocellular Cancer • Hepatology • Immunology

A marker of cccDNA transcription - hepatitis B core-related antigen (HBcrAg) - mimics HBV RNA decline during antiviral therapy with bulevirtide in chronic hepatitis delta (HDV) patients (EASL 2025) - No abstract available

Clinical • Hepatitis B • Hepatology • Infectious Disease • Inflammation

NTCP intronic polymorphism rs17556915 had no impact on HDV RNA levels and bulevirtide response in patients treated with bulevirtide (EASL 2025) - No abstract available

Clinical • Hepatology

Inhibition of hepatic bile salt uptake using the anti-HDV drug Bulevirtide attenuates inflammation in mouse models for colitis and diet-induced steatohepatitis (EASL 2025) - No abstract available

Preclinical • Gastroenterology • Gastrointestinal Disorder • Hepatology • Immunology • Inflammation

Quality of life in HDV-infected patients prior to bulevirtide treatment: chronic hepatitis versus compensated cirrhosis (EASL 2025) - No abstract available

Clinical • HEOR • Fibrosis • Hepatology • Immunology • Inflammation

Health-related quality of life in patients with chronic hepatitis D receiving bulevirtide and pegylated interferon: interim results from the SEE-D clinical trial (EASL 2025) - No abstract available

Clinical • HEOR • Hepatology • Inflammation

iCARE: Insights on competency advancement and recommendations for nurses managing HBV/HDV with bulevirtide – findings from a european advisory board (EASL 2025) - No abstract available

Hepatitis B • Hepatology

Patient centered-outcomes in HDV-treated patients with Bulevirtide (EASL 2025) - No abstract available

Clinical • Hepatology

Response-guided interferon add-on to bulevirtide treatment: updated real-world insights from the austrian hepatitis D cohort study (EASL 2025) - No abstract available

Clinical • Real-world • Real-world evidence • Hepatology • Inflammation

Exploring predictive factors for treatment response to Bulevirtide in Delta-positive patients (EASL 2025) - No abstract available

Biomarker • Clinical • Hepatitis B • Hepatology • Infectious Disease

Pharmacokinetics, pharmacodynamics, and safety of bulevirtide 10 mg once daily for 6 days in participants with moderate hepatic impairment and in matched control participants with normal hepatic function (EASL 2025) - No abstract available

Clinical • PK/PD data • Hepatology

Pharmacokinetics, pharmacodynamics, and safety of bulevirtide 10 mg once daily for 6 days in participants with severe renal impairment and in matched control participants with normal renal function (EASL 2025) - No abstract available

Clinical • PK/PD data • Renal Disease

Virological response and safety of combination treatment with bulevirtide and pegylated interferon in chronic hepatitis D patients with advanced fibrosis/cirrhosis: 48 weeks interim results from SEE-D trial (EASL 2025) - No abstract available

Clinical • Metastases • Fibrosis • Hepatology • Immunology • Inflammation

Improvement in 3 noninvasive tests through 144 weeks of bulevirtide monotherapy in patients with chronic hepatitis delta with and without virologic response (EASL 2025) - No abstract available

Clinical • Monotherapy • Non-invasive • Hepatology • Inflammation

Treatment response to bulevirtide leads to improvement of portal hypertension in patients with chronic hepatitis D virus infection: results from the prospective IMPHROVE-D study (EASL 2025) - No abstract available

Clinical • Cardiovascular • Hepatology • Infectious Disease • Inflammation • Portal Hypertension

Quantification of plasma HDV RNA by three commercially available assays in untreated and Bulevirtide-treated real-life patients with CHD: Robogene 2.0 vs. Altostar vs. Eurobioplex EBX071 (EASL 2025) - No abstract available

Clinical • Hepatology

Long risk of decompensation and HCC in patients with HDV-related compensated cirrhosis treated with Bulevirtide monotherapy for up to 144 weeks: the retrospective multicenter european study (Save-D) (EASL 2025) - No abstract available

Monotherapy • Retrospective data • Fibrosis • Hepatocellular Cancer • Hepatology • Immunology

Virological outcomes in patients with HDV-related compensated cirrhosis treated with Bulevirtide monotherapy for 144 weeks: a subanalysis of the retrospective multicenter european study (Save-D) (EASL 2025) - No abstract available

Monotherapy • Retrospective data • Fibrosis • Hepatology • Immunology

HBV reactivation in HBV/HDV coinfected patients during bulevirtide monotreatment (EASL 2025) - No abstract available

Clinical • Hepatitis B • Hepatology

Assessment of response and impact of safety treatment with bulevirtide in patients with chronic delta virus infection: an observational trial for evaluating long-term efficacy. The ARISTOTELE study (EASL 2025) - No abstract available

Clinical • Observational data • Infectious Disease